Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease-KOZANI STUDY

Translational Research

Volumn 155, Issue 5, 2010, Pages 238-246

  Kadoglou, Nikolaos P E ^a,b   Lampropoulos, Stilianos ^a   Kapelouzou, Alkistis ^b   Gkontopoulos, Argirios ^a   Theofilogiannakos, Efstratios K ^a   Fotiadis, Grigorios ^c   Kottas, George ^a  

^a Mamatsio General Hospital   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; APELIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; GHRELIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; TIROFIBAN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; APELIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; GHRELIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HOSPITAL ADMISSION; HUMAN; INSULIN RESISTANCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

EID: 77950807413     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2010.01.004     Document Type: Article

References (38)

1. Wilson P.W. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med 121 (2008) S15-S20
2. Shah A., Mehta N., and Reilly M.P. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr 32 (2008) 638-644
3. Tatemoto K., Hosoya M., Habata Y., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251 (1998) 471-476
4. Kleinz M.J., and Davenport A.P. Emerging roles of apelin in biology and medicine. Pharmacol Ther 107 (2005) 198-211
5. Kleinz M.J., Skepper J.N., and Davenport A.P. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 126 (2005) 233-240
6. Ronkainen V.P., Ronkainen J.J., Hänninen S.L., et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 21 (2007) 1821-1830
7. Malyszko J., Malyszko J.S., Pawlak K., and Mysliwiec M. Visfatin and apelin, new adipokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci 53 (2008) 32-36
8. Farkasfalvi K., Stagg M.A., Coppen S.R., et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 357 (2007) 889-895
9. Leeper N.J., Tedesco M.M., Kojima Y., et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 296 (2009) H1329-H1335
10. Chun H.J., Ali Z.A., Kojima Y., et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 118 (2008) 3343-3354
11. Hashimoto T., Kihara M., Imai N., et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 171 (2007) 1705-1712
12. Li Z., Bai Y., and Hu J. Reduced apelin levels in stable angina. Intern Med 47 (2008) 1951-1955
13. Cordido F., Isidro M.L., Nemiña R., and Sangiao-Alvarellos S. Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect. Curr Drug Discov Technol 6 (2009) 34-42
14. Kellokoski E., Kunnari A., Jokela M., Mäkelä S., Kesäniemi Y.A., and Hörkkö S. Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 58 (2009) 1572-1580
15. Kadoglou N.P.E., Sailer N., Moumtzouoglou A., et al. Novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrin Diab 35 (2008) 661-668
16. Peters A.L., and Schriger D.L. The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors. Am J Med 105 (1998) 15S-19S
17. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51 (1983) 606-607
18. Chandrasekaran B., Dar O., and McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 10 (2008) 725-732
19. Ronkainen V.P., Ronkainen J.J., Hänninen S.L., et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 21 (2007) 1821-1830
20. Weir R.A., Chong K.S., Dalzell J.R., et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 11 (2009) 551-558
21. Chen M.M., Ashley E.A., Deng D.X., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 (2003) 1432-1439
22. Halvorsen B., Otterdal K., Dahl T.B., et al. Atherosclerotic plaque stability-what determines the fate of a plaque?. Prog Cardiovasc Dis 51 (2008) 183-194
23. Singh V., and Deedwania P. Reducing morbidity and mortality in high risk patients with statins. Vasc Health Risk Manag 5 (2009) 495-507
24. Kadoglou N.P., Tsanikidis H., Kapelouzou A., et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism (2009) E-pub ahead of print
25. Skilton M.R., and Celermajer D.S. The effects of obesity-related peptides on the vasculature. Curr Vasc Pharmacol 4 (2006) 79-85
26. Caliskan Y., Gorgulu N., Yelken B., et al. Plasma ghrelin levels are associated with coronary microvascular and endothelial dysfunction in peritoneal dialysis patients. Ren Fail 31 (2009) 807-813
27. Yano Y., Toshinai K., Inokuchi T., et al. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 204 (2009) 590-594
28. Genís B.B., Granada M.L., Alonso N., et al. Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. Transplantation 84 (2007) 1248-1254
29. García E.A., and Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol 6 (2006) 142-147
30. Kleinz M.J., Maguire J.J., Skepper J.N., and Davenport A.P. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res 69 (2006) 227-235
31. Katugampola S.D., Pallikaros Z., and Davenport A.P. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 134 (2001) 143-149
32. Skilton M.R., Nakhla S., Sieveking D.P., Caterson I.D., and Celermajer D.S. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol 32 (2005) 839-844
33. Kellokoski E., Kummu O., Serpi R., et al. Ghrelin vaccination decreases plasma MCP-1 level in LDLR(-/-)-mice. Peptides 30 (2009) 2292-2300
34. Li W.G., Gavrila D., Liu X., Wang L., et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109 (2004) 2221-2226
35. Avallone R., Demers A., Rodrigue-Way A., et al. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway. Mol Endocrinol 20 (2006) 3165-3178
36. Tasci I., Erdem G., Ozgur G., et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 204 (2009) 222-228
37. Otto C., Otto B., Frost R.J., et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 44 (2007) 65-68
38. Kadoglou N.P., Gerasimidis T., Moumtzouoglou A., et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 35 (2008) 661-668